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Abstract Alcohol dependence (AD) has a large heritable
component. Genetic variation in genes involved in the absorp-
tion and elimination of ethanol have been associated with AD.
However, some of these polymorphisms are not present in an
African population. Previous studies have reported that a type
of AD which is characterized by anxious behaviour may be a
genetically specific subtype of AD. We investigated whether
variation in genes encoding cytochrome P450 2E1 (CYP2E1)
or acetaldehyde-metabolising enzymes (ALDH1A1, ALDH2)
might alter the risk of AD, with and without symptoms of
anxiety, in a Cape population with mixed ancestry. Eighty
case control pairs (one with AD, one without AD) were
recruited and individually matched for potential confounders.
Genotype data were available for 29 single-nucleotide poly-
morphisms (SNPs) across the three genes. Linkage disequi-
libriumD′ values were evaluated for all pairwise comparisons.
Allele and haplotype frequencies were compared between
cases and controls using a χ2 test. The ACAG haplotype in
block 4 of the ALDH1A1 gene provided evidence of an
association with AD (p=0.03) and weak evidence of an asso-
ciation with AD without symptoms of anxiety (p=0.06).
When a genetic score was constructed using SNPs showing
nominal evidence of association with AD, every extra risk
allele increased the odds of AD by 35 % (OR 1.35, 95%CI
1.08, 1.68, p=0.008) and the odds of having AD with anxiety
symptoms increased by 53 % (OR 1.53, 95%CI 1.14, 2.05,
p=0.004). Although our results are supported by previous
studies in other populations, they must be interpreted with
caution due to the small sample size and the potential
influence of population stratification.
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Introduction
Alcohol dependence (AD) is substantially heritable with
studies estimating that heritability is between 50 and 70 %
(Heath et al. 1997; Hiroi and Agatsuma 2005; Ystrom
et al. 2011; Young-Wolff et al. 2012). Genes associated
with AD include those coding for enzymes involved in
the absorption and elimination of ethanol such as alcohol
dehydrogenase (ADH), aldehyde dehydrogenase (ALDH)
and cytochrome P450 2E1 (CYP2E1) (Zakhari 2006;
Edenberg 2007). Metabolism of ethanol consists of two rate
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limiting reactions (Zakhari 2006). Firstly, ethanol is converted
to acetaldehyde, which is subsequently metabolized to
acetate. The first step is predominantly catalysed by alco-
hol dehydrogenases (ADH), with minor roles for cyto-
chrome P450 2E1 (CYP2E1) and catalase. In the second
step, acetaldehyde is metabolised by aldehyde dehydroge-
nases (ALDH). Acetaldehyde is considerably more toxic
than ethanol, and its accumulation leads to a highly aver-
sive reaction that includes anxiety, facial flushing, nausea,
and rapid heartbeat (Eriksson 2001).
Genetic variants that cause a build up of acetaldehyde,
either by rapid ethanol metabolism or reduced acetaldehyde
metabolism, have been found to be associated with lower risk
for AD and heavy drinking (Edenberg 2007). The frequency
of these genetic variants varies between ancestral groups
(Edenberg 2012). The two polymorphisms that have been
most strongly associated with AD in Asian populations,
ADH1B Arg47His (rs1229984) and ALDH2 Glu487Lys
(rs671), have little/no variation in one African population
(Goedde et al. 1992).
AD is a heterogeneous disorder, highly comorbid with
internalising disorders (Kessler et al. 1996). Various subtypes
of AD have previously been described each with different
reasons for developing an addiction, different withdrawal
syndromes, different prognoses, and different responses to
therapeutic approaches (Lesch et al. 1988). Research has
suggested there may be an anxious subtype of AD charac-
terized by high harm avoidance, high reward dependence,
and low novelty-seeking behaviour (Cloninger 1987). More
recently, reports have suggested this anxious AD may be a
genetically specific subtype of AD (Lee et al. 2010).
Therefore, if genetic markers could be used to identify this
subtype of AD, patient care could be improved by tailoring
treatment accordingly.
The median age of onset for AD (23 years of age) is much
later than for anxiety disorders (11 years of age) (Kessler et al.
2005). The risk of lifetime dependence to alcohol is far greater
for individuals who start drinking at an earlier age (Grant and
Dawson 1997). An adolescent cohort of individuals with AD
indentifies the most serious cases of AD, and anxiety symp-
toms would be expected to have been reported by this age.
We investigated whether variation in genes encoding
CYP2E1 or acetaldehyde-metabolising enzymes (ALDH1A1,
ALDH2) might alter the risk of AD in an adolescent Cape
population with mixed ancestry by performing systematic
haplotype association analyses to maximize the chances of
capturing functional variation. We also investigated the associa-
tion between a genotype risk score and AD. Investigating ge-
netic associations in different population groups is important in
order to replicate and validate previous findings, or where results
do not correlate it may indicate heterogeneity. Additionally, we
investigated whether AD with or without comorbid symptoms
of anxiety may be a genetically specific subtype of AD.
Methods
Participants
Details of the participants have been reported previously
(Ferrett et al. 2011). In brief, 80 case control pairs (one with
AD, one without AD) fromwithin the Cape Flats region (Cape
Town, South Africa) were individually matched for age (with-
in 1 year), gender (each group consisted of 47 females and 33
males), education level, language and socioeconomic status
(SES). The average participant was aged 14.8 years (sd 0.76)
and had completed 7.6 years (sd 0.82) of education. The
sample reflected the sociodemographic profile of the Cape
Flats population (100 % Coloured; Language, 69 %
Afrikaans, 31 % English; 86 % in households with formal
housing; and 85 % earning a gross annual income of less than
ZAR 100 000). Exclusion criteria included, but were not
limited to: mental retardation; lifetime DSM-IV Axis I diag-
noses other than AD (including the following disorders: de-
pressive, anxiety, psychotic, post-traumatic stress, eating, tic,
attention-deficit/hyperactivity, oppositional defiant, and con-
duct); less than 6 years of formal education; and lack of
proficiency in English or Afrikaans. Volunteers were screened
for eligibility after written informed assent/consent was ob-
tained from volunteers and parents or guardians.
The study protocol and procedures complied with and were
conducted in strict adherence to the guidelines contained in
the Declaration of Helsinki (2008). Full written approval to
conduct the study was obtained from the Western Cape
Education Department and the Research Ethics Committee
of the Stellenbosch University Faculty of Health Sciences.
Measures
Alcohol use A revised version of the Timeline Followback
(TLFB) procedure (Sobell and Sobell 1992), a semi-
structured, clinician-administered assessment of alcohol use
and drinking patterns, was used in collaboration with the
Kiddie Schedule for Affective Disorders and Schizophrenia
Present and Lifetime Versions (K-SADS-PL) (Kaufman et al.
1997) to elicit alcohol-use data. A standard drink was defined
as one beer or wine cooler, one glass of wine, or one 1.5-oz
shot of liquor (alone or in a mixed drink). ADwas defined by a
lifetime dosage in excess of 100 units plus a DSM-IV diag-
nosis of alcohol abuse or dependence. The control group were
non-drinkers (who had never consumed alcohol) and light
drinkers (lifetime dosage not exceeding 76 units of alcohol),
with no history of AD.
Psychopathology Total symptom counts from the K-SADS-
PL were recorded for generalised anxiety disorder. As previ-
ously mentioned, individuals with a diagnosis of anxiety
disorders were excluded from the study. However, individuals
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reporting low levels of anxiety symptoms, not severe enough
for a diagnosis of anxiety disorders, were included in the
study. A binary variable was generated for the presence or
absence of these anxiety symptoms in individuals with AD
(anxious-AD). Of the 80 individuals with AD, there were 59
individuals without any anxiety symptoms and 21 with anx-
iety symptoms.
Genotyping There were genotype data on a total of 29 single-
nucleotide polymorphisms (SNPs) (16 SNPs in ALDH1A1, 7
SNPs in ALDH2, 6 SNPs in CYP2E1). Genotyping was
carried out using a custom Illumina Infinium iSelect custom
6000 bead chip.
Genotype risk score We calculated a genotype risk score
using all SNPs moderately associated with outcome (chi-
square value greater than 1). The score was the unweighted
sum of the number of risk alleles (0, 1 or 2) at each of these
SNP loci. Separate genotype risk scores were created for the
outcomes of AD and anxious-AD.
Statistical analysis
The genotype distributions for each SNP in the control group
(without AD) were used to calculate deviation from Hardy–
Weinberg equilibrium (HWE) using a χ2 test, and those SNP’s
which did show evidence of deviation were excluded from
further analysis. Linkage disequilibrium (LD) D′ values were
evaluated for all marker pairs. Customised haplotype blocks
were defined in Haploview version 4.2 (Barrett et al. 2005).
Allele and haplotype frequencies were compared between
cases and controls using a χ2 test. Logistic regression models
were used to investigate the association between genotype risk
score and the outcomes of AD, or ADwith anxiety symptoms.
A Bonferroni correction was applied to address the issues
associated with multiple testing (Bland and Altman 1995). A
power calculation was performed using the Quanto software
(Version 1.2.4) (Gauderman and Morrison 2006). Statistical
analyses were performed using Haploview version 4.2
(Barrett et al. 2005) and Stata version 12.1 (StataCorp 2011).
Results
There was evidence that one SNP (rs348457) deviated from
HWE (p<0.001) and there was no genetic variation in another
SNP (rs671). Both these SNPs were excluded from our anal-
yses. This left a total of 27 SNPs in the analysis (15 for
ALDH1A1, 6 for ALDH2, 6 for CYP2E1). The allele fre-
quencies for the 27 SNPs are presented in Table 1. To correct
for the multiple testing of 27 SNPs in two disease models, a
threshold level of significance was calculated as p<0.0009.
This is a conservative estimate due to the LD between SNPs.
Given the number of tests, there was no evidence of any
associations other than one would expect by chance.
Linkage disequilibrium
The extent of LD between the SNPs was determined for
ALDH1A1 (Fig. 1), ALDH2 (Fig. 2) and CYP2E1 (Fig. 3).
Alcohol dependence analysis
A total of 160 individuals were included in the analysis (80
with AD, 80 without AD). There was some evidence of an
association between AD and rs6413419 in the CYP2E1 gene
(p=0.04) (Table 1). In the haplotype analysis there was some
evidence of an association with the ACAG haplotype in block
4 of the ALDH1A1 gene (p=0.03) (Table 2).
Alcohol dependence with anxiety symptoms analysis
A total of 80 individuals with AD were included in the
analysis (21 with anxiety symptoms, 59 without anxiety
symptoms). There was weak evidence of an association with
anxious-AD and rs63319 of the ALDH1A1 gene (p=0.10)
(Table 1). In the haplotype analysis there was weak evidence
of an association with the ACAG haplotype in block 4 of the
ALDH1A1 gene (p=0.06) (Table 2).
Genotype risk score
There were 8 SNPs (4 SNPs in ALDH1A1, 2 SNPs in
ALDH2, 2 SNPs in CYP2E1) associated with AD that were
included in this genotype risk score. This score ranged from 5
to 13. For every increase in genotype risk score (ie. for every
extra risk allele) the odds of AD increased by 35 % (OR 1.35,
95%CI 1.08, 1.68, p=0.008).
There were 8 SNPs (3 SNPs in ALDH1A1, 2 SNPs in
ALDH2, 3 SNPs in CYP2E1) associated with anxious-AD
that were included in this genotype risk score. This score
ranged from 5 to 16. For every increase in genotype risk score
(ie. for every extra risk allele) the odds of having AD with
anxiety symptoms (rather than AD without anxiety symptoms)
increased by 53% (OR 1.53, 95%CI 1.14, 2.05, p=0.004). The
effect of both genotype risk scores appeared to be linear,
although interpretation is limited due to a small number of
individuals at the extremes.
Power calculation
We performed a post hoc statistical power and sample size
analysis. Statistical power is defined as the probability of
rejecting the null hypothesis while the alternative hypothesis
is true. The results vary for each SNP investigated but assum-
ing an allele frequency of 0.9 (rs6413419), a population risk of
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0.1, an additive genetic model, an odds ratio of 3 (aa v. AA)
and significance set at 5 %, we had 27 % power. Using
the same assumptions but setting the power to 80 % we
would need a sample size approximately five times the
size of the current study (or ten times the size for the
anxious-AD analysis).
Discussion
Main findings and comparisons with the literature
Although AD is prevalent in South Africa (Williams et al.
2008; Peltzer et al. 2011) there has been a paucity of previous
research investigating genetic variants associated with this
phenotype in a South African population. The ACAG haplo-
type in block 4 of the ALDH1A1 gene had a frequency of
6.9 % in our cohort and provided some evidence of an asso-
ciation with AD. This haplotype was more frequent in indi-
viduals with AD than controls (10 % v. 3.8 %, p=0.03) and
more frequent in individuals with AD but without anxiety
symptoms than individuals with AD and anxiety symptoms
(12.7 % v. 2.4 %, p=0.06). Therefore, it is possible that this
haplotype may identify non-anxious AD as a genetically
specific subtype of AD. There were also encouraging findings
with regard to the genotype risk score.
The association between AD and the ACAG haplotype was
driven by rs11143443. This SNP is located upstream of the 5′
promoter region of the ALDH1A1 gene and has previously
been associated with AD in an African American population
(Liu et al. 2011). Genetic variation in the promoter region has
been reported to affect ALDH1A1 gene expression (Spence
et al. 2003), although to our knowledge no such gene expres-
sion data exist for this particular SNP. Liu et al. (Liu et al. 2011)
Table 1 Allele frequencies and associations with alcohol dependence or alcohol dependence with anxiety symptoms
Gene SNP Allele AD AD with anxiety symptoms
Case, control frequencies Chi square P value Case, control frequencies Chi square P value
ALDH1A1 rs8187998 A 1.000, 0.994 1.00 0.32 1.000, 1.000 − −
rs1888202 C 0.625, 0.619 0.01 0.91 0.548, 0.653 1.46 0.23
rs63319 A 0.538, 0.531 0.01 0.91 0.429, 0.576 2.72 0.10
rs8187974 A 0.006, 0.000 1.00 0.32 0.000, 0.008 0.36 0.55
rs2773806 G 0.256, 0.206 1.13 0.29 0.262, 0.254 0.01 0.92
rs1424482 G 0.506, 0.494 0.05 0.82 0.500, 0.508 0.01 0.92
rs8187876 G 0.850, 0.844 0.02 0.88 0.857, 0.847 0.02 0.88
rs11143429 A 0.644, 0.631 0.05 0.82 0.643, 0.644 0.00 0.99
rs6560311 C 0.719, 0.669 0.94 0.33 0.738, 0.712 0.11 0.75
rs2249978 G 0.519, 0.506 0.05 0.82 0.500, 0.525 0.08 0.78
rs1418187 G 0.612, 0.588 0.21 0.65 0.571, 0.627 0.41 0.52
rs4745209 G 0.338, 0.325 0.06 0.81 0.381, 0.322 0.48 0.49
rs7860980 C 0.956, 0.938 0.56 0.45 0.952, 0.958 0.02 0.89
rs4406477 A 0.569, 0.556 0.05 0.82 0.548, 0.576 0.10 0.75
rs11143443 G 0.138, 0.100 1.08 0.30 0.071, 0.161 2.10 0.15
ALDH2 rs2238151 G 0.219, 0.219 0.00 0.99 0.857, 0.754 1.92 0.17
rs2238152 A 0.162, 0.138 0.39 0.53 0.167, 0.161 0.01 0.93
rs4648328 A 0.162, 0.131 0.62 0.43 0.167, 0.161 0.01 0.93
rs7311852 C 0.031, 0.006 2.72 0.10 0.024, 0.034 0.10 0.75
rs4646778 A 0.162, 0.138 0.39 0.53 0.167, 0.161 0.01 0.93
rs7296651 C 0.594, 0.512 2.14 0.14 0.667, 0.568 1.26 0.26
CYP2E1 rs3813865 G 0.825, 0.819 0.02 0.88 0.857, 0.814 0.41 0.52
rs3813867 G 0.056, 0.050 0.06 0.80 0.024, 0.068 1.13 0.29
rs915906 A 0.544, 0.488 1.01 0.31 0.619, 0.517 1.30 0.25
rs6413419 G 0.931, 0.862 4.09 0.04 0.929, 0.932 0.01 0.94
rs743535 G 0.831, 0.819 0.09 0.77 0.857, 0.822 0.27 0.60
rs2515642 A 0.569, 0.569 0.00 0.99 0.524, 0.398 1.99 0.16
AD alcohol dependence. A total of 160 individuals were included in the AD analysis (80 with AD, 80 without AD). A total of 80 AD individuals were
included in the AD with anxiety analysis (21 with anxiety symptoms, 59 without anxiety symptoms)
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also reported evidence of an association between AD and a
haplotype in ALDH2, driven by rs7311852. The same SNP
provided weak evidence of an association with AD in our data.
However, the authors report that the positive association was
influenced by population stratification.
The CapeMixed Ancestry group, which has been shown to
have the greatest level of intercontinental admixture compared
to any other international population group, consists of indi-
viduals of Khoesan, Bantu-speaking African, European and
Asian ethnicity (Tishkoff et al. 2009; de Wit et al. 2010). A
principal components analysis, using genetic markers across
the genome, would be required to determine whether this
cohort consists of a single genetic population, and thus
whether our associations are influenced by population strati-
fication. Comparing the allele frequencies of individuals in
this study with populations in the HapMap project (Gibbs
et al. 2003) showed the frequencies to be intermediate be-
tween the Utah residents with ancestry from northern and
western Europe (CEU) and the Yoruba in Ibadan, Nigeria
(YRI) (data not shown).
Strengths, limitations and future directions
The main limitation of this study is the small sample size
which is further compounded in our pre-specified subgroup
analysis of AD with or without anxiety symptoms. Therefore,
Fig. 1 Haplotype block structure
for the ALDH1A1 gene on
chromosome 9. Haplotype blocks
are outlined. Figures represent D′
Fig. 2 Haplotype block structure for the ALDH2 gene on chromosome
12. Haplotype blocks are outlined. Figures represent D′
Fig. 3 Haplotype block structure for the CYP2E1 gene on chromosome
10. Haplotype blocks are outlined. Figures represent D′
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our findings must be interpreted with caution and should be
considered preliminary. This is especially true given that there
was no evidence of any association other than that which one
would expect by chance. However, we limited our anal-
yses to focus on three biologically relevant genes and
have been clear on the tests that have been performed
which is generally more important when dealing with
multiple comparisons (Perneger 1998).
This adolescent cohort contained extremely well defined
cases of AD as individuals with a diagnosis of comorbid
generalised anxiety disorder were excluded from the study.
Therefore, our power to identify a genetically specific subtype
of non-anxious AD will be greater than other cohorts of a
similar size. Our power calculation clearly indicates that larger
studies are required in this area. A potential limitation of this
selective cohort is that the results may not be generalisable to
the general population where AD tends to be highly comorbid
with other disorders. Additionally, as this is an adolescent
cohort, and the median age of onset for AD is 23 years of
age, it is possible that individuals included as controls in this
study may go on to develop AD. However, AD is inversely
associated with age of first drink and so individuals with AD
in this cohort are likely to have a more severe phenotype than
a control individual that goes onto develop AD at a later stage
(Grant and Dawson 1997).
For some SNPs the evidence of an association was stronger
in the AD analysis than in the anxious-AD analysis. This may
be because this is a marker associated with AD in general
rather than with a specific subtype of AD. Alternatively, this
may also be explained by the reduction in sample size between
the two analyses. This can be seen for the SNP rs7296651
where the effect size in the AD analysis is less extreme, but the
Table 2 ALDH1A1, ALDH2 and CYP2E1 haplotype frequencies and associations with alcohol dependence or alcohol dependence with anxiety
symptoms
Gene Block Haplotype Freq. AD AD with anxiety symptoms
Case control frequencies Chi square P value Case control frequencies Chi square P value
ALDH1A1 Block1 CA 0.48 0.491, 0.469 0.16 0.69 0.395, 0.525 2.12 0.15
GC 0.32 0.329, 0.319 0.04 0.85 0.418, 0.297 2.08 0.15
CC 0.14 0.134, 0.150 0.17 0.68 0.153, 0.127 0.18 0.67
GA 0.05 0.046, 0.062 0.40 0.53 0.034, 0.051 0.20 0.66
Block 2 AAGGC 0.33 0.332, 0.332 0.00 0.99 0.355, 0.324 0.13 0.72
GGGAC 0.16 0.191, 0.137 1.72 0.19 0.198, 0.189 0.02 0.89
AGAAA 0.15 0.150, 0.156 0.02 0.88 0.143, 0.153 0.02 0.88
AGGAA 0.10 0.089, 0.108 0.33 0.56 0.075, 0.094 0.15 0.70
AAGAC 0.08 0.089, 0.066 0.56 0.46 0.042, 0.105 1.55 0.21
Block 3 GG 0.49 0.503, 0.472 0.31 0.58 0.496, 0.505 0.01 0.91
AA 0.38 0.372, 0.378 0.02 0.90 0.424, 0.353 0.68 0.41
AG 0.11 0.110, 0.116 0.03 0.87 0.076, 0.122 0.67 0.41
Block 4 ACAA 0.44 0.425, 0.456 0.32 0.57 0.476, 0.406 0.61 0.44
GCGA 0.32 0.324, 0.324 0.00 0.99 0.380, 0.305 0.81 0.37
ACGA 0.11 0.100, 0.119 0.29 0.59 0.072, 0.111 0.51 0.48
ACAG 0.07 0.100, 0.038 4.88 0.03 0.024, 0.127 3.68 0.06
AAAG 0.05 0.037, 0.062 1.05 0.30 0.048, 0.034 0.17 0.68
ALDH2 Block 1 GCGGCC 0.39 0.402, 0.384 0.11 0.74 0.479, 0.375 1.42 0.23
GCGGCG 0.23 0.193, 0.260 2.03 0.15 0.189, 0.195 0.01 0.93
ACGGCG 0.21 0.211, 0.212 0.00 0.98 0.141, 0.236 1.66 0.20
GAAGAC 0.14 0.153, 0.122 0.65 0.42 0.162, 0.149 0.04 0.84
CYP2E1 Block 1 GCAGGA 0.38 0.390, 0.371 0.12 0.73 0.472, 0.360 1.63 0.20
GCGGGG 0.15 0.157, 0.150 0.03 0.87 0.130, 0.167 0.33 0.57
CCGGGG 0.11 0.124, 0.104 0.32 0.57 0.082, 0.139 0.91 0.34
GCGAGG 0.07 0.050, 0.094 2.30 0.13 0.048, 0.051 0.01 0.93
GCAGGG 0.07 0.067, 0.070 0.02 0.90 0.096, 0.056 0.79 0.37
AD alcohol dependence. The table lists haplotypes that have a frequency greater than 5 %. A total of 160 individuals were included in the AD
analysis (80 with AD, 80 without AD). A total of 80 AD individuals were included in the AD with anxiety analysis (21 with anxiety symptoms,
59 without anxiety symptoms)
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strength of evidence for the association is stronger than in the
anxious-AD analysis (AD analysis: OR 0.71, 95%CI 0.45 to
1.12, p=0.14, compared with anxious-AD analysis: OR 0.62,
95%CI 0.28 to 1.37, p=0.24). The same set of individuals
were used in the discovery and testing of the genetic risk
scores therefore, although we observed relatively large effect
sizes future work could look to validate these findings in an
independent sample.
This study increases the body of evidence investigating
genetic variants and AD in a genetically admixed population.
It is important to investigate this type of population in order to
replicate previous findings, as well as attempting to identify
genetic variants for complex disorders (de Wit et al. 2010).
Meta-analyses of genetic studies will be needed to identify
genetically-specific subtypes of AD, potentially providing
insights into the biological mechanism of these disorders.
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